The stock rose 0.50% or $0.07 reaching $15.2 per share. (NYSE:VRX) (TSE:VRX) in a research note released on Friday. Valeant Pharmaceuticals International has a 1-year low of $8.31 and a 1-year high of $32.74.
The company has mean EPS estimate of 0.96 reported by 16 number of analyst for the quarter ending Current Qtr.(Sep2010). Equities research analysts predict that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current year. Morgan Stanley downgraded the shares of VRX in report on Thursday, December 15 to "Equal Weight" rating. Zacks' sales averages are an average based on a survey of research analysts that that provide coverage for Valeant Pharmaceuticals International.
Valeant's revenue also declined year-over-year, to US$2.23 billion from US$2.42 billion and adjusted earnings fell to $951 million for the second quarter of 2017, from $1.09 billion last year. Valeant Pharmaceuticals International had a negative net margin of 14.96% and a positive return on equity of 58.02%. Second quarter section revenue of $6.8 million and an Adjusted EBITDA loss of $0.7 million; a year over year increase in revenue of 13% and a decrease in Adjusted EBITDA of $1.2 million. Next quarter's EPS is estimated at $0.90 with next year's EPS projected to be $3.78. Tech Data Corp had 10 analyst reports since August 18, 2015 according to SRatingsIntel. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has "Buy" rating given on Wednesday, June 28 by Cantor Fitzgerald.
In order to reach an opinion and communicate the value and volatility of a covered security, analysts research public financial statements, listen in on conference calls and talk to managers and the customers of a company, typically in an attempt to capture the findings for a research report. BidaskClub cut shares of Valeant Pharmaceuticals Intl from a "buy" rating to a "hold" rating in a research report on Monday, July 31st. Stifel Nicolaus reissued a "buy" rating and issued a $35.00 price target on shares of Valeant Pharmaceuticals International in a research report on Friday, June 30th. Four investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of "Hold" and a consensus target price of $16.96. (NYSE:VRX) (TSE:VRX) saw some unusual options trading on Thursday.
The volume of the particular stock is the shares bought and sold in a single trading day. VRX stock price revealed optimistic move of 6.28% comparing average price of last 200 days. The firm's market cap is $5.26 billion. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has "Underperform" rating given on Monday, March 21 by Mizuho. "(NYSE:VRX) Short Interest Down 23.9% in June" was first reported by StockNewsTimes and is owned by of StockNewsTimes.
COPYRIGHT VIOLATION WARNING: This piece was first published by BNB Daily and is the sole property of of BNB Daily. Bank of Montreal Can increased its stake in Valeant Pharmaceuticals International by 9.8% in the second quarter. DE SCHUTTER RICHARD U bought 20,000 shares worth $278,000. Following the completion of the acquisition, the director now owns 70,572 shares in the company, valued at $980,950.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. After this purchase, 174,000 common shares of VRX are directly owned by the insider, with total stake valued at $2,632,620. Morgan Stanley increased its position in shares of Valeant Pharmaceuticals International by 48.2% in the first quarter. Gulf International Bank UK Ltd boosted its stake in Valeant Pharmaceuticals International by 1.1% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company's stock worth $105,000 after buying an additional 1,500 shares during the period. Marathon Trading Investment Management Llc reported 0.09% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). WMS Partners LLC acquired a new stake in Valeant Pharmaceuticals International during the first quarter valued at about $116,000. IFP Advisors has an ownership of 128,305 stocks of the specialty pharmaceutical firms shares valued at $2,220,000 after scooping up an extra 509 shares through out the quarter.
Several equities research analysts recently commented on VRX shares. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).